FDA approves new drug to treat COPD
March 03, 2011 |
For Immediate Release
*Note: Daliresp has been approved as the trade name for roflumilast.
March 3, 2011 - The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).
Roflumilast, a new drug class for the treatment of COPD, is an inhibitor of an enzyme called phosphodiesterase type 4 (PDE-4). It is indicated for people with severe COPD to treat the symptoms of cough and excess mucus linked to bronchitis. Roflumilast is not intended to treat another form of COPD which involves primary emphysema.
To read the full press release, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm.